Trial Profile
A Randomized Phase IIa, Multi-center, Double-blind, Placebo-controlled Study to Assess the Safety, Feasibility, Tolerability, and Efficacy of a New Buccal Film of Montelukast in Patients With Mild to Moderate Alzheimer's Disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Apr 2024
Price :
$35
*
At a glance
- Drugs Montelukast (Primary)
- Indications Alzheimer's disease
- Focus Proof of concept; Registrational; Therapeutic Use
- Acronyms BUENA
- Sponsors IntelGenx Corp.
- 17 Apr 2024 Status changed from active, no longer recruiting to completed.
- 01 Aug 2023 According to an IntelGenx Technologies media release, the company looking forward to completing the BUENA trial in the first quarter of 2024 and to reporting initial trial results the following quarter.
- 01 Aug 2023 Planned number of patients changed from 70 to 54.